SCHEMBL23914740

SCHEMBL23914740

C=C1OC(=O)c2c(C)cccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
MYC P01106 1/20 0.40
DPP4 P27487 1/20 0.40
KDM4E B2RXH2 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38
DAO P14920 1/20 0.37
MEN1 O00255 2/20 0.37
ALDH1A1 P00352 2/20 0.37
POLB P06746 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL166198 0.80 ALOX15 (0.52) CA1CA2CA7CA9MYC
SCHEMBL29539686 0.80 ALOX15 (0.52) CA1CA2CA7CA9MYC
SCHEMBL23048499 0.78 TDP1 (0.39) KDM4EALDH1A1HPGD
SCHEMBL28456026 0.75 CA1 (0.44) CA1CA2CA7CA9MYC
SCHEMBL451628 0.72 CA1 (0.46) CA1CA2CA7CA9MYC
SCHEMBL14023417 0.72 CA1 (0.46) CA1CA2CA7CA9MYC
SCHEMBL19735974 0.72 CA1 (0.46) CA1CA2CA7CA9MYC
SCHEMBL25617190 0.72 ALOX15 (0.39) KDM4ECYP1A2CYP2C19MEN1ALDH1A1
SCHEMBL6036681 0.70 TDP2 (0.52) CA1CA2CA7CA9MYC
SCHEMBL4161497 0.70 CA1 (0.52) CA1CA2CA7CA9MYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GILEAD SCIENCES, INC. 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS S1PR1, S1PR3, S1PR2 CA1 4775/4885CA2 3170/4885CA7 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.